Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.77 USD
+0.16 (2.04%)
Updated May 3, 2024 04:00 PM ET
After-Market: $7.77 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/20/24 |
---|---|
Current Quarter | -0.24 |
EPS Last Quarter | -0.30 |
Last EPS Surprise | -20.00% |
ABR | 1.00 |
Earnings ESP
|
-4.17% |
---|---|
Current Year | -1.24 |
Next Year | -2.13 |
EPS (TTM) | -0.85 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.24 | -0.28 | -1.24 | -2.13 |
# of Estimates | 2 | 2 | 2 | 2 |
Most Recent Consensus | -0.25 | -0.30 | -1.30 | -2.40 |
High Estimate | -0.23 | -0.25 | -1.17 | -1.86 |
Low Estimate | -0.25 | -0.30 | -1.30 | -2.40 |
Year ago EPS | -0.15 | -0.19 | -0.84 | -1.24 |
Year over Year Growth Est. | -60.00% | -47.37% | -47.62% | -72.18% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 1 | 1 | 1 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.24 | -0.28 | -1.24 | -2.13 |
7 Days Ago | -0.24 | -0.28 | -1.24 | -2.13 |
30 Days Ago | -0.24 | -0.28 | -1.24 | -2.13 |
60 Days Ago | -0.30 | -0.38 | -1.54 | -1.16 |
90 Days Ago | -0.24 | -0.24 | -0.99 | -1.16 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.25 | -0.30 | -1.30 | -2.40 |
Zacks Consensus Estimate | -0.24 | -0.28 | -1.24 | -2.13 |
Earnings ESP | -4.17% | -9.09% | -5.26% | -12.68% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.30 | -0.21 | -0.19 | -0.15 | NA |
Estimate | -0.25 | -0.23 | -0.21 | -0.25 | NA |
Difference | -0.05 | 0.02 | 0.02 | 0.10 | 0.02 |
Surprise | -20.00% | 8.70% | 9.52% | 40.00% | 9.56% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more